74 related articles for article (PubMed ID: 22204157)
21. How do we operationalize the individualization of ESA dosing and target Hb levels?
Finkelstein FO
Nephrol News Issues; 2013 Jun; 27(7):Supp 17-8. PubMed ID: 23855146
[No Abstract] [Full Text] [Related]
22. Excessive level of parathyroid hormone may induce the reduction of recombinant human erythropoietin effect on renal anemia.
Fujita Y; Inoue S; Horiguchi S; Kuki A
Miner Electrolyte Metab; 1995; 21(1-3):50-4. PubMed ID: 7565462
[TBL] [Abstract][Full Text] [Related]
23. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism.
Trunzo JA; McHenry CR; Schulak JA; Wilhelm SM
Surgery; 2008 Dec; 144(6):915-8; discussion 919. PubMed ID: 19040997
[TBL] [Abstract][Full Text] [Related]
24. [Erythropoietin resistance as initial presentation of ANCA-positive intra-alveolar hemorrhage in a hemodialysis patient].
Sirvent AE; Arenas MD; Egea JJ; Gil MT
Nefrologia; 2004; 24(3):296-7. PubMed ID: 15283323
[No Abstract] [Full Text] [Related]
25. Infrequent dosing of subcutaneous erythropoietin for the treatment of anemia in patients on CAPD.
Bunke M; Bartlett DK; Brier ME; Golper TA
Adv Perit Dial; 1993; 9():331-5. PubMed ID: 8105957
[TBL] [Abstract][Full Text] [Related]
26. [Therapy of renal anemia with recombinant human erythropoietin].
Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A
Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487
[TBL] [Abstract][Full Text] [Related]
27. Treatment of anaemia in CAPD patients with recombinant human erythropoietin.
Ramello A; Malcangi U; Bruno M; Perosa P; Reina E; Rizzuto A; Nasini MG; Carozzi S
Adv Perit Dial; 1990; 6():308-11. PubMed ID: 1982834
[TBL] [Abstract][Full Text] [Related]
28. Erythropoietin, an update, and where to in the future?
Sulková S
EDTNA ERCA J; 1998; 24(3):30-2, 35. PubMed ID: 10392076
[TBL] [Abstract][Full Text] [Related]
29. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
30. [A case of the good effect of low doses of erythropoietin].
Shostka GD; Dobronravov VA; Vasil'ev AN
Urol Nefrol (Mosk); 1991; (5):74-5. PubMed ID: 1755131
[No Abstract] [Full Text] [Related]
31. Erythropoietin and chronic renal failure.
Drüeke T; Zins B; Naret C; Casadevall N; Goureau Y; Bererhi L; Zingraff J; Delons S; Kreis H; Varet B
Nouv Rev Fr Hematol (1978); 1989; 31(2):97-8. PubMed ID: 2771635
[No Abstract] [Full Text] [Related]
32. Erythropoietin-resistant refractory renal anemia: effects of oral L-carnitine supplementation.
Kawabata M; Kasuga S; Hara H; Suyama S; Moriyama K; Takabatake T
Clin Nephrol; 2001 Mar; 55(3):265-6. PubMed ID: 11316253
[No Abstract] [Full Text] [Related]
33. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
34. [Treatment with intravenous iron and ferritin level].
Fernández-Gallego J; Martín MA; Sujan S; Vega E
Nefrologia; 2010; 30(3):371-2. PubMed ID: 20514109
[No Abstract] [Full Text] [Related]
35. [Effects erythropoietin on experimental anemia in rats with chronic renal failure].
Ling SS; Zhou Y; Sun WL; Zhu DC; Zhang HY; Tang GZ; Jin YF; Zhu JZ
Yao Xue Xue Bao; 1992; 27(6):412-7. PubMed ID: 1442067
[TBL] [Abstract][Full Text] [Related]
36. Serum erythropoietin titers in the anemia of chronic renal failure and other hematological states.
Urabe A; Saito T; Fukamachi H; Kubota M; Takaku F
Int J Cell Cloning; 1987 May; 5(3):202-8. PubMed ID: 3598244
[TBL] [Abstract][Full Text] [Related]
37. [Current management of renal anemia in patients with chronic kidney disease at the predialysis stage].
Kuriyama S; Otsuka Y; Uetake D; Shirai I; Hosoya T
Nihon Jinzo Gakkai Shi; 2007; 49(5):505-10. PubMed ID: 17695813
[TBL] [Abstract][Full Text] [Related]
38. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
[TBL] [Abstract][Full Text] [Related]
39. Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin.
Verbeelen D; Hauglustaine D; Sennesael J
Neth J Med; 1988 Aug; 33(1-2):60-7. PubMed ID: 3247012
[No Abstract] [Full Text] [Related]
40. Recombinant human erythropoietin for anaemia in thalassaemia minor patients on dialysis.
Kagan A; Sinay-Trieman L; Bar-Khayim Y
Nephrol Dial Transplant; 1995 Dec; 10(12):2375-6. PubMed ID: 8808253
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
